MynxGrip vascular closure device use in pediatric neurointerventional procedures

Research output: Contribution to journalArticle

Abstract

OBJECTIVE The aim of this paper was assess the effcacy and safety of using the MynxGrip arterial closure device in pediatric neuroendovascular procedures where the use of closure devices remains off-label despite their validation and widespread use in adults. METHODS A retrospective review of all pediatric patients who underwent diagnostic or interventional neuroendovascular procedures at the authors' institution was performed. MynxGrip use was predicated by an adequate depth of subcutaneous tissue and common femoral artery (CFA) diameter. Patients remained on supine bedrest for 2 hours after diagnostic procedures and for 3 hours after therapeutic procedures. Patient demographics, procedural details, hemostasis status, and complications were recorded. RESULTS Over 36 months, 83 MynxGrip devices were deployed in 53 patients (23 male and 30 female patients; mean age 14 years) who underwent neuroendovascular procedures. The right-side CFA was the main point of access for most procedures. The mean CFA diameter was 6.24 mm and ranged from 4 mm to 8.5 mm. Diagnostic angiography comprised 46% of the procedures. A single device failure occurred without any sequelae; the device was extracted, and hemostasis was achieved by manual compression with the placement of a Safeguard compression device. No other immediate or delayed major complications were recorded. CONCLUSIONS MynxGrip can be used safely in the pediatric population for effective hemostasis and has the advantage of earlier mobilization.

Original languageEnglish (US)
Pages (from-to)466-470
Number of pages5
JournalJournal of Neurosurgery: Pediatrics
Volume21
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Pediatrics
Femoral Artery
Equipment and Supplies
Hemostasis
Equipment Failure
Early Ambulation
Bed Rest
Subcutaneous Tissue
Vascular Closure Devices
Angiography
Demography
Safety
Population
Therapeutics

Keywords

  • Common femoral artery
  • Endovascular procedures
  • Interventional procedures
  • MynxGrip
  • Vascular closure device
  • Vascular disorders

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

@article{02db82a2a15947299b8c61376f9b0dbe,
title = "MynxGrip vascular closure device use in pediatric neurointerventional procedures",
abstract = "OBJECTIVE The aim of this paper was assess the effcacy and safety of using the MynxGrip arterial closure device in pediatric neuroendovascular procedures where the use of closure devices remains off-label despite their validation and widespread use in adults. METHODS A retrospective review of all pediatric patients who underwent diagnostic or interventional neuroendovascular procedures at the authors' institution was performed. MynxGrip use was predicated by an adequate depth of subcutaneous tissue and common femoral artery (CFA) diameter. Patients remained on supine bedrest for 2 hours after diagnostic procedures and for 3 hours after therapeutic procedures. Patient demographics, procedural details, hemostasis status, and complications were recorded. RESULTS Over 36 months, 83 MynxGrip devices were deployed in 53 patients (23 male and 30 female patients; mean age 14 years) who underwent neuroendovascular procedures. The right-side CFA was the main point of access for most procedures. The mean CFA diameter was 6.24 mm and ranged from 4 mm to 8.5 mm. Diagnostic angiography comprised 46{\%} of the procedures. A single device failure occurred without any sequelae; the device was extracted, and hemostasis was achieved by manual compression with the placement of a Safeguard compression device. No other immediate or delayed major complications were recorded. CONCLUSIONS MynxGrip can be used safely in the pediatric population for effective hemostasis and has the advantage of earlier mobilization.",
keywords = "Common femoral artery, Endovascular procedures, Interventional procedures, MynxGrip, Vascular closure device, Vascular disorders",
author = "Tahaamin Shokuhfar and Hurley, {Michael C.} and Anas Al-Smadi and Ansari, {Sameer A.} and Potts, {Matthew B.} and Jahromi, {Babak S.} and Alden, {Tord D.} and Ali Shaibani",
year = "2018",
month = "5",
day = "1",
doi = "10.3171/2017.11.PEDS17481",
language = "English (US)",
volume = "21",
pages = "466--470",
journal = "Journal of Neurosurgery: Pediatrics",
issn = "1933-0707",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - MynxGrip vascular closure device use in pediatric neurointerventional procedures

AU - Shokuhfar, Tahaamin

AU - Hurley, Michael C.

AU - Al-Smadi, Anas

AU - Ansari, Sameer A.

AU - Potts, Matthew B.

AU - Jahromi, Babak S.

AU - Alden, Tord D.

AU - Shaibani, Ali

PY - 2018/5/1

Y1 - 2018/5/1

N2 - OBJECTIVE The aim of this paper was assess the effcacy and safety of using the MynxGrip arterial closure device in pediatric neuroendovascular procedures where the use of closure devices remains off-label despite their validation and widespread use in adults. METHODS A retrospective review of all pediatric patients who underwent diagnostic or interventional neuroendovascular procedures at the authors' institution was performed. MynxGrip use was predicated by an adequate depth of subcutaneous tissue and common femoral artery (CFA) diameter. Patients remained on supine bedrest for 2 hours after diagnostic procedures and for 3 hours after therapeutic procedures. Patient demographics, procedural details, hemostasis status, and complications were recorded. RESULTS Over 36 months, 83 MynxGrip devices were deployed in 53 patients (23 male and 30 female patients; mean age 14 years) who underwent neuroendovascular procedures. The right-side CFA was the main point of access for most procedures. The mean CFA diameter was 6.24 mm and ranged from 4 mm to 8.5 mm. Diagnostic angiography comprised 46% of the procedures. A single device failure occurred without any sequelae; the device was extracted, and hemostasis was achieved by manual compression with the placement of a Safeguard compression device. No other immediate or delayed major complications were recorded. CONCLUSIONS MynxGrip can be used safely in the pediatric population for effective hemostasis and has the advantage of earlier mobilization.

AB - OBJECTIVE The aim of this paper was assess the effcacy and safety of using the MynxGrip arterial closure device in pediatric neuroendovascular procedures where the use of closure devices remains off-label despite their validation and widespread use in adults. METHODS A retrospective review of all pediatric patients who underwent diagnostic or interventional neuroendovascular procedures at the authors' institution was performed. MynxGrip use was predicated by an adequate depth of subcutaneous tissue and common femoral artery (CFA) diameter. Patients remained on supine bedrest for 2 hours after diagnostic procedures and for 3 hours after therapeutic procedures. Patient demographics, procedural details, hemostasis status, and complications were recorded. RESULTS Over 36 months, 83 MynxGrip devices were deployed in 53 patients (23 male and 30 female patients; mean age 14 years) who underwent neuroendovascular procedures. The right-side CFA was the main point of access for most procedures. The mean CFA diameter was 6.24 mm and ranged from 4 mm to 8.5 mm. Diagnostic angiography comprised 46% of the procedures. A single device failure occurred without any sequelae; the device was extracted, and hemostasis was achieved by manual compression with the placement of a Safeguard compression device. No other immediate or delayed major complications were recorded. CONCLUSIONS MynxGrip can be used safely in the pediatric population for effective hemostasis and has the advantage of earlier mobilization.

KW - Common femoral artery

KW - Endovascular procedures

KW - Interventional procedures

KW - MynxGrip

KW - Vascular closure device

KW - Vascular disorders

UR - http://www.scopus.com/inward/record.url?scp=85048239238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048239238&partnerID=8YFLogxK

U2 - 10.3171/2017.11.PEDS17481

DO - 10.3171/2017.11.PEDS17481

M3 - Article

VL - 21

SP - 466

EP - 470

JO - Journal of Neurosurgery: Pediatrics

JF - Journal of Neurosurgery: Pediatrics

SN - 1933-0707

IS - 5

ER -